Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Presentation / Abstract • Phase 1/2EULAR 2026 presentation Mon, Jun 1, 2026
Company profile
Cabaletta Bio, Inc.
Pipeline1 asset
- rese-celCABA-201 / CD19 / Autologous fully human 4-1BB CD19-CAR T cell therapy / Autoimmune diseaseDermatomyositisRegistrationalrecruitingUSAntisynthetase syndromeRegistrationalrecruitingUSImmune-mediated necrotizing myopathyPhase 1/2recruitingUS
Latest news8 items
All newsCabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
Presentation / Abstract • Phase 1/2EULAR 2026 abstract release Wed, Jun 3, 2026, 7:00 AM EDT
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Presentation / Abstract • Phase 1/2EULAR oral presentation Thu, Jun 4, 2026, 9:15 AM BST
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
Presentation / AbstractASGCT poster presentation Thu, May 14, 2026, 7:00 AM EDT
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Presentation / Abstract
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presentation / Abstract • Phase 1/2